//www.igerbera.com/journals/jamaophthalmology en-us Thu, 16 Mar 2023 00:00:00 GMT Thu, 16 Mar 2023 11:43:53 GMT Silverchair jamams@jamanetwork.org support@www.igerbera.com //www.igerbera.com/journals/jamaophthalmology/fullarticle/2802726 Thu, 16 Mar 2023 00:00:00 GMT This case report describes a vitreous eruption of a choroidal melanoma in a patient aged 64 years who presented with blurry vision. 141 3 e226043 10.1001 / jamaophthalmol.2022.6043 2802726 //www.igerbera.com/journals/jamaophthalmology/fullarticle/2802725 Thu, 16 Mar 2023 00:00:00 GMT This case report discusses a diagnosis of thelaziasis in a female patient aged 81 years who presented with a foreign body sensation in the left eye for 1 month. 141 3 e226297 10.1001 / jamaophthalmol.2022.6297 2802725 //www.igerbera.com/journals/jamaophthalmology/fullarticle/2802728 Wed, 01 Mar 2023 00:00:00 GMT The Original Investigation titled “Changes in Retinal Sensitivity Associated With Cotoretigene Toliparvovec in X-Linked Retinitis Pigmentosa With RPGR Gene Variations,” published online February 9, 2023, was corrected to fix the spelling of the first nonauthor collaborator’s name on PubMed. This article was corrected online. 141 3 293 293 10.1001/jamaophthalmol.2023.0716 2802728 //www.igerbera.com/journals/jamaophthalmology/fullarticle/2802711 Wed, 01 Mar 2023 00:00:00 GMT Mission Statement: To be the indispensable source of ophthalmic knowledge by promptly publishing innovative, clinically relevant research through consistent and authoritative peer review and, thereby, to be the first choice of authors for their important manuscripts. 141 3 222 222 10.1001 / jamaophthalmol.2022.4097 2802711 //www.igerbera.com/journals/jamaophthalmology/fullarticle/2801416 Wed, 01 Mar 2023 00:00:00 GMT 一个nti–vascular endothelial growth factor (VEGF) agents given as intravitreous injections are well-established and effective treatments for the 2 major vision-threatening complications of diabetic retinopathy (DR): center-involved diabetic macular edema (CI-DME) and proliferative DR (PDR). Together, these 2 complications account for the majority of cases of visual loss from DR, estimated to be about 2.5 million cases of moderate or severe visual impairment worldwide in 2015. 141 3 223 225 10.1001/jamaophthalmol.2023.0496 2801416 //www.igerbera.com/journals/jamaophthalmology/fullarticle/2801308 Wed, 01 Mar 2023 00:00:00 GMT This case report describes a patient with mpox (monkeypox) who presented with sight-threatening necrotizing blepharoconjunctivitis. 141 3 285 288 10.1001 / jamaophthalmol.2022.6253 2801308 //www.igerbera.com/journals/jamaophthalmology/fullarticle/2801307 Wed, 01 Mar 2023 00:00:00 GMT 一个n 81-year-old woman was referred for darkly pigmented corneal lesions affecting the corneal endothelium and stroma after uncomplicated right cataract surgery 2 years earlier. She was being treated with maintenance loteprednol, 0.5%, eye drops for persistent low-grade anterior uveitis. What would you do next? 141 3 289 290 10.1001 / jamaophthalmol.2022.6308 2801307 //www.igerbera.com/journals/jamaophthalmology/fullarticle/2801306 Wed, 01 Mar 2023 00:00:00 GMT The deep learning (DL) approach is a recent development in research on the automation of medical diagnostics using machine learning. This type of statistical learning is not based on biophysical (mechanistic) models but on training (for parameter estimation) using a sample of population data. There are issues about robustness in performance when testing on new data sets in uncontrolled conditions separate from validation experiments. The use of DL in diagnostic modeling has been demonstrated in recent years with very encouraging results in the assessment of diabetic retinopathy, geographic atrophy in age-related macular degeneration, and cardiovascular disease when using images of the retina. 141 3 240 241 10.1001 / jamaophthalmol.2022.6036 2801306 //www.igerbera.com/journals/jamaophthalmology/fullarticle/2801305 Wed, 01 Mar 2023 00:00:00 GMT Management of retinitis pigmentosa and other inherited retinal dystrophies has progressively evolved toward gene therapy, especially after the first successful treatment using an adeno-associated viral vector (AAV8) with gene delivery into retinal photoreceptors. The recently completed phase 1 XIRIUS trial has expanded this gene delivery approach to a potential treatment of X-linked retinitis pigmentosa (XLRP), commonly caused by mutations in the retinitis pigmentosa GTPase regulator (RPGR) gene. 141 3 283 284 10.1001 / jamaophthalmol.2022.6436 2801305 //www.igerbera.com/journals/jamaophthalmology/fullarticle/2801304 Wed, 01 Mar 2023 00:00:00 GMT Primary open-angle glaucoma (POAG) is a multifactorial disease process with an interplay of protective and disease-causing factors dictating the balance between retinal ganglion cell (RGC) survival and death. The role of blood flow to the optic nerve and retina clearly plays a role. The interaction between various blood pressure (BP) parameters and glaucoma has been the subject of intense investigation for decades, with conflicting results. Similarly, studies have varied in their findings regarding an association between a diagnosis of systemic hypertension and glaucoma. 141 3 258 259 10.1001 / jamaophthalmol.2022.6515 2801304 //www.igerbera.com/journals/jamaophthalmology/fullarticle/2801303 Wed, 01 Mar 2023 00:00:00 GMT This case report describes a 37-year-old female individual who presented with sudden-onset blurred vision in both eyes 4 days after testing positive for COVID-19. 141 3 291 293 10.1001 / jamaophthalmol.2022.6255 2801303 //www.igerbera.com/journals/jamaophthalmology/fullarticle/2801302 Wed, 01 Mar 2023 00:00:00 GMT This decision analytical model investigates the ability of a deep learning system to assess neurologic dysfunction in Parkinson disease using fundus images. 141 3 234 240 10.1001 / jamaophthalmol.2022.5928 2801302 //www.igerbera.com/journals/jamaophthalmology/fullarticle/2801301 Wed, 01 Mar 2023 00:00:00 GMT This cohort study investigates the association of blood pressure with rates of change in the macular ganglion cell complex among patients with glaucoma. 141 3 251 257 10.1001 / jamaophthalmol.2022.6092 2801301 //www.igerbera.com/journals/jamaophthalmology/fullarticle/2801300 Wed, 01 Mar 2023 00:00:00 GMT This post hoc analysis of the XIRIUS and XOLARIS studies investigates how changes in visual function associated with cotoretigene toliparvovec gene therapy in participants with RPGR-variant X-linked retinitis pigmentosa compare with those of untreated individuals. 141 3 275 283 10.1001 / jamaophthalmol.2022.6254 2801300 //www.igerbera.com/journals/jamaophthalmology/fullarticle/2801007 Wed, 01 Mar 2023 00:00:00 GMT Interstitial cystitis, also known as painful bladder syndrome, is characterized by urinary urgency, frequency, and nocturia, often accompanied by bladder and pelvic pain ranging from mild to severe. Interstitial cystitis affects approximately 1 million people in the US, most of them women. Pentosan polysulfate (PPS) (Elmiron; Janssen Pharmaceuticals) was approved by the US Food and Drug Administration (FDA) in 1996 for the treatment of interstitial cystitis and remains the only FDA-approved drug for this disease. However, it was not until 2018 that Pearce et al reported a case series of 6 women who were long-term users of PPS and had a pigmentary maculopathy with distinctive signs on fundus autofluorescence and near-infrared imaging. The most prominent symptoms were difficulty reading and prolonged dark adaptation. During the ensuing 4 years, several groups have identified a maculopathy associated with users of PPS, provided evidence to support a dose-response association, and expanded the spectrum of the maculopathy in users to early manifestations and severe cases of atrophy. The mean (SD) duration of PPS use in patients with the associated maculopathy was 15.0 (5.7) years in a recent comprehensive review that summarized previous studies through 2021, and the median (IQR) was 14 (10.2-18.9) years in a large (74 patients), recently published multicenter case series. 141 3 266 267 10.1001 / jamaophthalmol.2022.6158 2801007 //www.igerbera.com/journals/jamaophthalmology/fullarticle/2801006 Wed, 01 Mar 2023 00:00:00 GMT This cohort study evaluates 2-year outcomes after drug cessation in patients with pentosan polysulfate–associated maculopathy. 141 3 260 266 10.1001 / jamaophthalmol.2022.6093 2801006 //www.igerbera.com/journals/jamaophthalmology/fullarticle/2801005 Wed, 01 Mar 2023 00:00:00 GMT This economic evaluation determines the cost-effectiveness of aflibercept monotherapy vs bevacizumab first, then aflibercept for suboptimal response, in treating patients with diabetic macular edema. 141 3 268 274 10.1001 / jamaophthalmol.2022.6142 2801005 //www.igerbera.com/journals/jamaophthalmology/fullarticle/2800631 Wed, 01 Mar 2023 00:00:00 GMT The current next available appointment for a child to be seen by a pediatric ophthalmologist in the San Francisco Bay Area, California, is approximately 6 months. This is similar to most other regions in the US. How do we frame this substantial difficulty in accessing pediatric eye care in the US? 141 3 249 250 10.1001 / jamaophthalmol.2022.6011 2800631 //www.igerbera.com/journals/jamaophthalmology/fullarticle/2800630 Wed, 01 Mar 2023 00:00:00 GMT This cross-sectional study analyzes the geographic distribution of pediatric ophthalmologists in 2022 and compares the distribution to population demographic characteristics in the US. 141 3 242 249 10.1001 / jamaophthalmol.2022.6010 2800630 //www.igerbera.com/journals/jamaophthalmology/fullarticle/2800482 Wed, 01 Mar 2023 00:00:00 GMT This case series study investigated the clinical features and prognoses associated with fungal endophthalmitis resulting from contaminated medical products. 141 3 226 233 10.1001 / jamaophthalmol.2022.5927 2800482

map